Therapeutic drug monitoring (TDM) has been more widely used in small molecule agents, such as immuno-suppressants, antiepileptic drugs and antibiotics, with less attention in the field of therapeutic biological agents. Monoclonal drugs represented by tumor necrosis factor alpha (TNF-α) inhibitors have shown a good relationship between exposure and efficacy in clinical studies. There are corresponding guidelines and consensus for the recommendations of TDM based on current research evidence. Therefore, this paper introduced the current evidence, strategies and considerations for TDM in the optimal treatment of adalimumab from the perspective of adalimumab TDM to provide references for the clinical practice of adalimumab TDM.
ObjectiveTo systematically review the factors influencing plasma concentration of lamotrigine (LTG) in the treatment of epilepsy in children.Methods Databases including PubMed, EMbase, The Cochrane Library, CNKI, WanFang Data, VIP and CBM were electronically searched to collect clinical studies on the factors influencing plasma concentration of LTG in the treatment of epilepsy in children from database inception to December 2020. Two researchers independently screened the literature, extracted data, and assessed the risk of bias of the included studies. A systematic review was then performed to analyze the factors influencing plasma concentration of LTG in the treatment of epilepsy in children. ResultsA total of 21 studies were included. The results of systematic review suggested that dosage and some combination drugs (valproic acid, carbamazepine, phenytoin sodium, topiramate, ethosuximide, rufinamide, fluoxetine, clonazepam, clobazam and ethinylestradiol) were potential factors influencing LTG concentration. Four gene polymorphisms (UGT1A4 142T>G, UGT1A4 219C>T, UGT1A4 163G>A, and OCT1 M408V A>G), age, weight, sex, and combination drugs (phenobarbital and levetiracetam) might affect the plasma concentration of LTG in children. The effects of oxcarbazepine, 16 gene polymorphisms (UGT1A4 *3 T>G, UGT2B7 211G>T, UGT2B7 372A>G, UGT2B7 735A>G, UGT2B7 801T>A, UGT2B7 802C>T, UGT2B7 161C>T, SCN1A IVS591G>A, SCN2A c.56G>A, SCN2A c.59G>A, MDR1 1236 C>T, MDR1 2677 G>T/A, MDR1 3435 C>T, SLC22A1 1022C>T, ABCB1 3435 C>T and ABCB1 1236C>T), ketogenic diet, and ethnicity (Uygur/Han) on the plasma concentration of LTG in children were not found. Conclusion The plasma concentration of LTG in the treatment of epilepsy in children is affected by many factors, and more high-quality prospective studies should be carried out to further clarify the factors influencing the plasma concentration of LTG in children.